Pegaptanib sodium for neovascular age-related macular degeneration: Third-year safety results of the VEGF inhibition study in ocular neovascularisation (VISION) trial

British Journal of Ophthalmology

Volumn 92, Issue 12, 2008, Pages 1606-1611

  Singerman, L J ^a   Masonson, H ^b   Patel, M ^c   Adamis, A P ^d   Buggage, R ^e   Cunningham, E ^f,g   Goldbaum, M ^h   Katz, B ⁱ   Guyer, D ^j  

^a Retina Associates of Cleveland   (United States)

^b Ophthotech Corp   (United States)

^c Optherion Inc   (United States)

^d Jerini Ophthalmic   (United States)

^e PFIZER INC   (United States)

^f CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Eyetech Inc   (United States)

ⁱ Danube Pharmaceutials Inc   (United States)

^j SV Life Sciences   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL CELL GROWTH FACTOR; PEGAPTANIB;

ANTERIOR CHAMBER INFLAMMATION; ARTICLE; CATARACT; CLINICAL TRIAL; CONJUNCTIVAL HEMORRHAGE; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA EDEMA; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ELECTROCARDIOGRAM; ENDOPHTHALMITIS; ENZYME INHIBITION; EYE INFECTION; EYE PAIN; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; INFESTATION; INTRAOCULAR PRESSURE; LACRIMATION; MAJOR CLINICAL STUDY; MEDIASTINUM DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEOPLASM; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; OCULAR PRURITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RETINA DISEASE; RHEGMATOGENOUS RETINAL DETACHMENT; SIDE EFFECT; SKIN DISCOLORATION; SUBCUTANEOUS TISSUE DISORDER; THORAX DISEASE; TRAUMATIC CATARACT; VASCULAR DISEASE; VISUAL ACUITY; VITAL SIGN; VITREOUS FLOATERS; VITREOUS HEMORRHAGE; VITREOUS OPACITY;

AGED; APTAMERS, NUCLEOTIDE; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAOCULAR PRESSURE; MACULAR DEGENERATION; MALE; TONOMETRY, OCULAR; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 57149091202     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2007.132597     Document Type: Article

References (28)

1. LaCootsr J, Moritz DR. Li B, et al. Angiogenesis- independent endothelial protection of liver: role of VEGFR-1. Science 2003:299:890-3.
2. Kitamoto Y, Tokunaga H, Tomita K. Vascular endothelial growth factor is an essential molecule for mouse kidney development: glomerulogenesis and nephrogenesis. J Clin Invest 1997;99:2351-7.
3. Eremina V, Sood M. Haigh J. et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003;111:707-16.
4. Nissen NN, Polverini PJ, Koch AE. et al. Vascular endothelial growth factor mediates angiogenic activity during the proliferate phase of wound healing. Am J Pathol 1998;152:1445-52.
5. Deodato B, Arsic N. Zentilin L, et al. Recombinant AAV vector encoding human VEGF165 enhances wound healing. Gene Ther 2002;9:777-85.
6. Ryan AM, Eppler DB. Hagler KE. et al. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol Pathol 1999;27:78-86.
7. Fraser HM, Wilson H, Rudge JS, et al. Single injections of vascular endothelial growth factor trap block ovulation in the macaque and produce a prolonged, doserelated suppression of ovarian function. J Clin Endocrinol Metab 2005;90:1114-22.
8. Garner HP, Vu TH, Ryan AM. et al. VEGF couples hypertrophic cartilage remodelling, ossification and angiogenesis during endochondral bone formation. Nat Med 1999;5:623-8.
9. Kamba T, Tarn BY, Mashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006;290:H560-76.
10. Storkebaum E, Lambrechts D, Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 2004;26:943-4.
11. Blaauwgeers HG, Holtkamp GM, Rutten H, et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol 1999;155:421-8.
12. Blaauwgeers HG, Holtkamp GM, Rutten H, et al. Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol 2005;167:1451-9.
13. Nishijima K, Ng Y-S, Zhong L, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007;171:53-67.
14. Kilic U, Kilic E, Jarve A, et al. Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERI-1/2 and Akt pathways. J Neurosci 2006;26:12439-46.
15. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005;69(3 Suppl):25-33S.
16. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99:1232-9.
17. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. Clin Oncol 2007;25:5180-6.
18. van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA 2005;293:1509-13.
19. Avery RL, Peariman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695.e1-15.
20. Ishida S, Usui T. Yamashiro K, et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 2003;198:483-9.
21. Ishida S, Usui T, Yamashiro K, et al. VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 2003;44:2155-62.
22. Usui T, Ishida S, Yamashiro K, et al. VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci 2004;45:368-74.
23. Gragoudas ES, Adamis AP, Cunningham ET Jr. et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16.
24. Chakravarthy U, Adamis AP, Cunningham ET Jr. et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006;113:1508-21.
25. D'Amico DJ, Masonson HM, Patel M, et al. Pegaptanib sodium for neovascular agerelated macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006;113:992-1001.
26. Wlotzka B, Leva S, Eschgfäller B, et al. In vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleotide-based therapeutic substance class. Proc Natl Acad Sci USA 2002;99:8898- 902.
27. Apte RS, Modi M, Masonson H, et al. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology 2007;114:1702-12.
28. Duan Y, Mo J, Klein R. AMD is associated with incident myocardial infarction among elderly Americans. Ophthalmology 2007;114:732-7.